Peroxisome proliferator–activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice
Rajeev Sharma, Pallawi Torka – 24 November 2008
Improved survival with nonselective beta blockers
Ulrich Thalheimer, Jaime Bosch, David Patch, Andrew Burroughs – 24 November 2008
Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor α, reduced glutathione, and transforming growth factor β–dependent mechanisms
Francisco Javier Cubero, Natalia Nieto – 24 November 2008 – Because of the contribution of ethanol and polyunsaturated fatty acids (PUFAs) to alcoholic liver disease, we investigated whether chronic ethanol administration and arachidonic acid (AA) could synergistically mediate Kupffer cell (KC) activation and modulate the stellate cell (HSC) fibrogenic response.
Proteomic profiling reveals the prognostic value of adenomatous polyposis coli–end‐binding protein 1 in hepatocellular carcinoma
Tatsuya Orimo, Hidenori Ojima, Nobuyoshi Hiraoka, Shigeru Saito, Tomoo Kosuge, Tatsuhiko Kakisaka, Hideki Yokoo, Kazuaki Nakanishi, Toshiya Kamiyama, Satoru Todo, Setsuo Hirohashi, Tadashi Kondo – 24 November 2008 – Histological differentiation is a major pathological parameter associated with poor prognosis in patients with hepatocellular carcinoma (HCC) and the molecular signature underlying HCC differentiation may involve key proteins potentially affecting the malignant characters of HCC.
Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models
Douglas G. Farmer, Fady Kaldas, Dean Anselmo, Masamichi Katori, Xiu‐Da Shen, Charles Lassman, Marian Kaldas, Martine Clozel, Ronald W. Busuttil, Jerzy Kupiec‐Weglinski – 24 November 2008 – This study investigated the effects of dual endothelin (ET) receptor blockade in rat models of liver ischemia and reperfusion injury (IRI).
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B–containing lipoproteins
Wei Qiu, Lisa Federico, Mark Naples, Rita Kohen Avramoglu, Reza Meshkani, Jing Zhang, Julie Tsai, Mahmood Hussain, Kezhi Dai, Jahangir Iqbal, Christopher D. Kontos, Yasuo Horie, Akira Suzuki, Khosrow Adeli – 24 November 2008 – Hepatic apolipoprotein B (apoB) lipoprotein production is metabolically regulated via the phosphoinositide 3‐kinase cascade; however, the role of the key negative regulator of this pathway, the tumor suppressor phosphatase with tensin homology (PTEN), is unknown.
Anti‐CD81 antibodies can prevent a hepatitis C virus infection in vivo
Philip Meuleman, Joseph Hesselgesser, Matthew Paulson, Thomas Vanwolleghem, Isabelle Desombere, Hans Reiser, Geert Leroux‐Roels – 24 November 2008 – The viral life cycle of the hepatitis C virus (HCV) has been studied mainly using different in vitro cell culture models. Studies using pseudoviral particles (HCVpp) and more recently cell culture–derived virus (HCVcc) suggest that at least three host cell molecules are important for HCV entry in vitro: the tetraspanin CD81, the scavenger receptor class B member I, and the tight junction protein Claudin‐1.
Continuing Success with Down‐Staging of Hepatocellular Carcinoma
James D. Perkins – 24 November 2008
Evidence for no relevance of anti–major histocompatibility complex class i–related chain a antibodies in liver transplantation
Mehmet Uzunel, Haxiaobieke Kasimu, Meghnad Joshi, Xupeng Ge, Jining Liu, Bo Xu, Marie Jaksch, Carl Jorns, Grzegorz Nowak, Suchitra Sumitran‐Holgersson – 24 November 2008 – The polymorphic major histocompatibility complex class I–related chain A (MICA) antigen is being increasingly recognized as a potential target molecule for immune cells during allograft rejection. Here we studied whether MICA is a target antigen for antibodies in liver transplant patients.
The potential impact of using donations after cardiac death on the liver transplantation program and waiting list in the state of Sao Paulo, Brazil
Eleazar Chaib, Eduardo Massad – 24 November 2008 – Liver transplantation was first performed at the University of Sao Paulo School of Medicine in 1968. Since then, the patient waiting list for liver transplantation has increased at a rate of 150 new cases per month. Liver transplantation itself rose 1.84‐fold (from 160 to 295) from 1988 to 2004. However, the number of patients on the liver waiting list jumped 2.71‐fold (from 553 to 1500). Consequently, the number of deaths on the liver waiting list moved to a higher level, from 321 to 671, increasing 2.09‐fold.